-
Je něco špatně v tomto záznamu ?
Narrative update of clinical trials with antihypertensive drugs in children and adolescents
J. Redon, T. Seeman, D. Pall, L. Suurorg, K. Kamperis, S. Erdine, E. Wühl, G. Mancia
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu systematický přehled
NLK
Directory of Open Access Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
- Publikační typ
- systematický přehled MeSH
INTRODUCTION: To date, our knowledge on antihypertensive pharmacological treatment in children and adolescents is still limited because there are few randomized clinical trials (CTs), hampering appropriate management. The objective was to perform a narrative review of the most relevant aspects of clinical trials carried out in primary and secondary hypertension. METHODS: Studies published in PubMed with the following descriptors: clinical trial, antihypertensive drug, children, adolescents were selected. A previous Cochrane review of 21 randomized CTs pointed out the difficulty that statistical analysis could not assess heterogeneity because there were not enough data. A more recent meta-analysis, that applied more stringent inclusion criteria and selected 13 CTs, also concluded that heterogeneity, small sample size, and short follow-up time, as well as the absence of studies comparing drugs of different classes, limit the utility. RESULTS: In the presented narrative review, including 30 studies, there is a paucity of CTs focusing only on children with primary or secondary, mainly renoparenchymal, hypertension. In trials on angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics, a significant reduction of both SBP and DBP in mixed cohorts of children with primary and secondary hypertension was achieved. However, few studies assessed the effect of antihypertensive drugs on hypertensive organ damage. CONCLUSIONS: Given the increasing prevalence and undertreatment of hypertension in this age group, innovative solutions including new design, such as 'n-of-1', and optimizing the use of digital health technologies could provide more precise and faster information about the efficacy of each antihypertensive drug class and the potential benefits according to patient characteristics.
Department of Medical Clinical Pharmacology University of Debrecen Debrecen Hungary
Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark
Department of Pediatrics 2nd Faculty of Medicine Charles University Prague Prague Czechia
Hypertension and Atherosclerosis Center Marmara University School of Medicine Istanbul Turkey
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031234
- 003
- CZ-PrNML
- 005
- 20230127131107.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fcvm.2022.1042190 $2 doi
- 035 __
- $a (PubMed)36479567
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Redon, Josep $u INCLIVA Research Institute, CIBERObn Institute of Health Charles III, University of Valencia, Madrid, Spain
- 245 10
- $a Narrative update of clinical trials with antihypertensive drugs in children and adolescents / $c J. Redon, T. Seeman, D. Pall, L. Suurorg, K. Kamperis, S. Erdine, E. Wühl, G. Mancia
- 520 9_
- $a INTRODUCTION: To date, our knowledge on antihypertensive pharmacological treatment in children and adolescents is still limited because there are few randomized clinical trials (CTs), hampering appropriate management. The objective was to perform a narrative review of the most relevant aspects of clinical trials carried out in primary and secondary hypertension. METHODS: Studies published in PubMed with the following descriptors: clinical trial, antihypertensive drug, children, adolescents were selected. A previous Cochrane review of 21 randomized CTs pointed out the difficulty that statistical analysis could not assess heterogeneity because there were not enough data. A more recent meta-analysis, that applied more stringent inclusion criteria and selected 13 CTs, also concluded that heterogeneity, small sample size, and short follow-up time, as well as the absence of studies comparing drugs of different classes, limit the utility. RESULTS: In the presented narrative review, including 30 studies, there is a paucity of CTs focusing only on children with primary or secondary, mainly renoparenchymal, hypertension. In trials on angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics, a significant reduction of both SBP and DBP in mixed cohorts of children with primary and secondary hypertension was achieved. However, few studies assessed the effect of antihypertensive drugs on hypertensive organ damage. CONCLUSIONS: Given the increasing prevalence and undertreatment of hypertension in this age group, innovative solutions including new design, such as 'n-of-1', and optimizing the use of digital health technologies could provide more precise and faster information about the efficacy of each antihypertensive drug class and the potential benefits according to patient characteristics.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Seeman, Tomas $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University Prague, Prague, Czechia
- 700 1_
- $a Pall, Dénes $u Department of Medical Clinical Pharmacology, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Suurorg, Lagle $u Tallinn Children's Hospital, Tallinn, Estonia
- 700 1_
- $a Kamperis, Konstantinos $u Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
- 700 1_
- $a Erdine, Serap $u Hypertension and Atherosclerosis Center, Marmara University School of Medicine, Istanbul, Turkey
- 700 1_
- $a Wühl, Elke $u Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Mancia, Giuseppe $u University of Milano-Bicocca, Milan, Italy
- 773 0_
- $w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 9, č. - (2022), s. 1042190
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36479567 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131059 $b ABA008
- 999 __
- $a ok $b bmc $g 1889419 $s 1182567
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 9 $c - $d 1042190 $e 20221121 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
- LZP __
- $a Pubmed-20230119